Search Results
Found 2 results
510(k) Data Aggregation
(189 days)
NTW
The PAXgene™ Blood RNA System consists of a blood collection tube (PAXgene™ Blood RNA Tube) and nucleic acid purification kit (PAXgene™ Blood RNA Kit). It is intended for the collection, storage, and transport of blood and stabilization of intracellular RNA in a closed tube and subsequent isolation and purification of host RNA from whole blood for RT-PCR used in molecular diagnostic testing.
Performance characteristics for the PAXgene™ Blood RNA System have only been established with "cfos and IL1B." The user is responsible for establishing appropriate PAXgene™ Blood RNA System performance characteristics for other target transcripts.
PAXgene Blood RNA Kit is for the purification of intracellular RNA from whole blood collected in the PAXgene Blood RNA Tube. When the kit is used in conjunction with the PAXgene Blood RNA Tube, the system provides purified intracellular RNA from whole blood for RT-PCR used in molecular diagnostic testing.
Performance characteristics for the PAXgene Blood RNA System have only been established with FOS and IL1B gene transcripts. The user is responsible for establishing appropriate PAXgene Blood RNA System performance characteristics for other target transcripts.
The PAXgene™ Blood RNA System consists of:
- PAXgene™ Blood RNA tubes
- · PAXgene™ Blood RNA kit.
The PAXgene™ Blood RNA tube is of a sterile, plastic, evacuated blood collection tube containing stabilization solution (tetradecyl trimethyl-ammonium oxalate and tartaric acid. These components serve to lyse cells, protect RNA molecules from degradation by ribonucleases (RNases) and prevent induction of gene expression. The kit consists of 5 aqueous buffer solutions for resuspending, binding, washing, and eluting RNA, RNase-free water, proteinase K. an RNase-Free DNase set, spin columns, microcentrifuge tubes, processing tubes, and secondary blood collection tube closures.
Here's an analysis of the provided text regarding the PAXgene™ Blood RNA System, focusing on the acceptance criteria and the study proving it, as per your requested format:
1. Table of Acceptance Criteria and Reported Device Performance
The provided 510(k) summary (K082150) does not explicitly state quantitative acceptance criteria or detailed device performance metrics in a readily extractable table format. Instead, it focuses on demonstrating substantial equivalence to a predicate device (K042613) by showing that the RNA obtained using the updated system (with QIAcube automation) is "compatible with molecular diagnostic applications such as mRNA transcript level determination by RT-PCR."
The core assertion is: "Therefore the processing of RNA by the automated protocol on QIAGEN's QIAcube is equivalent to the manual process as described in K042613."
Implicit Acceptance Criteria (derived from the justification of equivalence):
Acceptance Criteria Category | Specific Criteria (Implicit from Equivalence Claim) | Reported Device Performance |
---|---|---|
RNA Compatibility | RNA obtained using the automated protocol on QIAGEN's QIAcube must be compatible with molecular diagnostic applications. | "The RNA obtained from the QIAcube is compatible with molecular diagnostic applications such as mRNA transcript level determination by RT-PCR." |
Equivalence to Predicate | The automated RNA purification process must be equivalent to the manual process of the predicate device (K042613) for RNA quality and quantity. | "the processing of RNA by the automated protocol on QIAGEN's QIAcube is equivalent to the manual process as described in K042613." |
Target Transcripts | Performance characteristics for "cfos and IL1B" must be maintained. (This is an existing statement from the predicate's intended use and not a new criterion for this submission). | Performance for cfos and IL1B is implicitly maintained due to demonstrated equivalence to the predicate, which had established performance for these. |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify the sample size used for the test set or the data provenance (e.g., country of origin, retrospective or prospective nature of the data). The information provided is very high-level, stating only that "Design Control activities performed demonstrated the RNA obtained from the QIAcube is compatible..." This suggests an internal validation study, but no details on the participants or samples are given.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts
This information is not provided in the document. The study described is a technical validation of RNA compatibility, not a diagnostic study requiring expert consensus on clinical ground truth.
4. Adjudication Method for the Test Set
This information is not applicable/not provided as the study did not involve human interpretation or a "test set" in the sense of comparing human reads or diagnostic outcomes. It was an analytical performance study.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
A Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This type of study is more relevant for diagnostic imaging or interpretation where different readers evaluate cases. The PAXgene™ Blood RNA System is a pre-analytical device for RNA purification.
6. Standalone (Algorithm Only Without Human-in-the-Loop Performance) Study
The study described could be considered a form of "standalone" evaluation in that it evaluates the automated RNA purification process (the "algorithm" or automated protocol) on QIAGEN's QIAcube in isolation, without involving human interpretation of the purification process itself. However, "standalone" usually refers to the performance of a diagnostic algorithm independent of human input in the diagnostic decision. Here, the "performance" is the quality and yield of the RNA. The document focuses on demonstrating that the RNA produced by the automated system is equivalent to that produced by the manual system of the predicate device, for subsequent molecular diagnostic testing.
7. Type of Ground Truth Used
The "ground truth" in this context is the quality and quantity of RNA deemed acceptable for downstream molecular diagnostic applications, specifically RT-PCR, as well as the equivalence to the RNA produced by the predicate manual method. This is established through the "Design Control activities" and presumably involved analytical measurements (e.g., RNA yield, purity, integrity, and successful amplification of target transcripts like cfos and IL1B). It is an analytical validation against established laboratory standards and the performance of the predicate.
8. Sample Size for the Training Set
This information is not applicable/not provided. The PAXgene™ Blood RNA System is a chemical and mechanical system for RNA purification; it does not involve machine learning or AI models that require a "training set" in the conventional sense. The "training" here would be the development and optimization of the automated protocol itself.
9. How the Ground Truth for the Training Set Was Established
This information is not applicable/not provided for the same reasons as point 8. The "ground truth" for developing the automated protocol would have been achieving optimal RNA quality and yield comparable to the manual method, established through iterative testing and analytical measurements.
Ask a specific question about this device
(49 days)
NTW
The PAXgene™ Blood RNA System consists of a blood collection tube (PAXgene™ Blood RNA Tube) and nucleic acid purification kit (PAXgene™ Blood RNA Kit). It is intended for the collection, storage, and transport of blood and stabilization of intracellular RNA in a closed tube and subsequent isolation and purification of host RNA from whole blood for RT-PCR used in molecular diagnostic testing.
Performance characteristics for the PAXgene™ Blood RNA System have only been established with "cfos and IL1B." The user is responsible for establishing appropriate PAXgene™ Blood RNA System performance characteristics for other target transcripts.
The PAXgene™ Blood RNA System consists of:
- the PAXgene™ Blood RNA tubes and .
- the PAXgene™ Blood RNA kit. .
The PAXgene™ Blood RNA tube is of a sterile, plastic, evacuated blood collection tube containing stabilization solution (tetradecyl trimethyl-ammonium oxalate and tartaric acid. These components serve to lyse cells, protect RNA molecules from degradation by ribonucleases (RNases) and prevent induction of gene expression.
The kit consists of 5 aqueous buffer solutions for resuspending, binding, washing, and eluting RNA, RNase-free water, proteinase K, an RNase-Free DNase set, spin columns, microcentrifuge tubes, processing tubes, and secondary blood collection tube closures.
The provided text details the performance characteristics and studies for the PAXgene™ Blood RNA System, intended for the collection, storage, and purification of intracellular RNA from whole blood for RT-PCR.
1. Table of Acceptance Criteria and Reported Device Performance
Parameter | Acceptance Criteria | Reported Device Performance |
---|---|---|
RNA Yield | ≥ 3 µg/tube (A260 nm) | Achieved (specific values not always given, but "all samples... fulfilled the acceptance criteria" and "in the expected ranges") |
RNA Purity | A260/A280 ratio between 1.8 and 2.2 | Achieved ("all samples... fulfilled the acceptance criteria" and "in the expected ranges") |
Integrity (CFOS/18S rRNA) | CFOS within 2.34 CT | Achieved ("within the acceptance range") |
Integrity (IL1B/18S rRNA) | IL1B within 1.94 CT | Achieved ("within the acceptance range") |
Genomic DNA (gDNA) Contamination | Percentage of gDNA in total nucleic acid preparation | All samples "fulfilled the acceptance criteria" |
RT-PCR Inhibition | Kit components do not introduce inhibition for an RT-PCR assay | "All samples demonstrated that the kit components do not introduce any inhibition" |
Reproducibility (% CV) | Within-run, inter-user, inter-lot | Varies: |
- Repeatability (quadruplicate per donor pool, per lot/user): Min/max % CV 3.4-28.8, overall 11.9%
- Reproducibility (per user, between lots): Min/max % CV 8.7-20.1, overall 14.9%
- Reproducibility (between lots and users): Min/max % CV 8.7-23.1, overall 16.4% |
| PAXgene Tube Stability (25°C) | Draw volume, liquid additive volume, closure performance, pH, conductivity, density, RNA yield, purity, CFOS/18S rRNA & IL1B/18S rRNA stability | All physical/chemical attributes and functional performance were within expected ranges for 6 months (sponsor claims 19 months based on accelerated studies) |
| PAXgene Kit Component Stability | Recovery of input RNA, variability of recovery, degree of inhibition, pH, conductivity, density, Proteinase K & DNase I activity, bioburden | All parameters in expected ranges for 6 months real-time storage; no bioburden; acceptable performance after extreme temperature simulation |
| RNA In Situ Stability (various temperatures/times/freeze-thaw) | RNA yield, purity, integrity (CFOS/18S rRNA, IL1B/18S rRNA) within acceptance range | All samples at all time points, temperatures, and freeze/thaw cycles were within the acceptance range (with one unspecified exception) |
| Linearity/Reportable Range (CFOS) | 0.2 to 7.8 ng total input nucleic acid; up to 25% DNA without affecting performance | Met |
| Linearity/Reportable Range (IL1B) | 0.1 to 7.8 ng total input nucleic acid; up to 5% DNA without affecting performance | Met |
2. Sample Sizes and Data Provenance
- Test Set (Precision/Reproducibility of RT-PCR Assays):
- K2EDTA samples: 5 donors, 5 tubes/donor (25 tubes total), 10 ml blood/tube. RNA isolated via OIAzol and RNeasy, pooled, concentrated.
- PAXgene samples: 48 donors, 8 tubes/donor (384 PAXgene tubes total), 2.5 ml blood/tube. RNA purified, DNase treated, concentrated, pooled.
- Reproducibility Design: 3 different component lots, 3 different experimenters, 3 different laboratories (equipment), on 3 different days.
- Each "run" (9 runs total) involved: 2 RNA samples (K=calibrator, T=test), each with 10 replicates. This generated 180 ΔCT values and 90 ΔΔCT values.
- Test Set (Precision/Reproducibility of PAXgene Blood RNA System - Experiment 1):
- 14 donors (WBC: 4.8-11.0 x 10^6 cells/ml blood)
- 12 tubes/donor (168 PAXgene tubes total)
- Test Set (Precision/Reproducibility of PAXgene Blood RNA System - Experiment 2):
- 30 donors (WBC: 4.8-11.0 x 10^6 cells/ml blood)
- 12 tubes/donor (360 PAXgene tubes total)
- Blood from 3 donors pooled and aliquoted into empty tubes to create 10 donor pools with 36 tubes each.
- Test Set (RNA Purity, DNA Contamination, RNA Yield):
- 10 donors
- 2 PAXgene tubes/donor (20 tubes total) + 1 EDTA tube/donor (10 EDTA tubes) for WBC count.
- Test Set (RT-PCR Inhibition):
- 22 blank eluates from columns.
- HeLa cell RNA used as template.
- Test Set (PAXgene Tube Stability):
- Functional tests: 60 tubes/time point (TTP) for accelerated studies (120 tubes total), 60 tubes/TTP for real-time study (810 tubes scheduled, 6 months data presented).
- Functional performance: 10 donors per time point for RNA yield, purity, CFOS/IL1B relative levels (3 time points for blood-filled tubes storage at 18-25°C x 2 preparations = 60 measurements).
- Test Set (PAXgene Kit Component Stability):
- Two reagent sets per time point for functional stability (4 blank eluates, 8 RNA eluates).
- Test Set (RNA In Situ Stability):
- Multiple experiments with 10 donors each. Number of PAXgene tubes per donor varied (6, 10, 12, 14 tubes/donor), resulting in totals of 60, 100, 120, and 140 tubes for different conditions.
- Data Provenance: The studies appear to be prospective, performed by the applicant (PreAnalytiX GmbH) to demonstrate the device's performance. The applicant is based in Switzerland (GmbH). The data is generated in a lab setting, not clinical real-world data from multiple countries.
3. Number of Experts and Qualifications for Ground Truth
The document does not mention the use of experts to establish a ground truth for the "test set" in the context of diagnostic interpretation (e.g., radiologists evaluating images). This device is a sample collection and purification system, not an interpretative diagnostic device. The ground truth for its performance is instead based on quantitative measurements of RNA yield, purity, integrity, and the absence of inhibitors. These are objective measures determined by laboratory instrumentation (e.g., spectrophotometers, Q-RT-PCR machines, BioAnalyzer).
However, "experimenters" and "technicians" are mentioned:
- Precision/Reproducibility of O-RT-PCR Duplex Assays: "3 different experimenters"
- Precision/Reproducibility of PAXgene Blood RNA System (both Experiments 1 & 2): "3 technicians"
Their specific qualifications (e.g., years of experience) are not provided, but they are implied to be trained laboratory personnel.
4. Adjudication Method
Not applicable. The "ground truth" for this device is based on objective, quantifiable laboratory measurements (e.g., RNA yield, purity ratios, Ct values), not on subjective expert interpretation requiring adjudication.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No. An MRMC comparative effectiveness study is not applicable for this type of device (RNA collection and purification system). Such studies are typically used for diagnostic imaging or interpreted assays where human readers are involved in making diagnostic decisions, and the AI aims to assist or replace them. This device is a sample preparation tool, and its "performance" is measured analytically, not by human reader accuracy.
6. Standalone (Algorithm Only) Performance
Yes, the studies described are essentially "standalone" performance evaluations of the device and its components. The PAXgene Blood RNA System's analytical performance (e.g., RNA yield, purity, integrity) is assessed directly through laboratory assays, without human intervention in the "decision-making" loop. Its function is to prepare RNA for downstream molecular diagnostic testing (RT-PCR), meaning its performance is evaluated on its ability to produce high-quality RNA suitable for such assays. The Q-RT-PCR assays run on the RNA extracted by the system are designed to evaluate the RNA quality produced by the device, not to perform a diagnosis.
7. Type of Ground Truth Used
The ground truth used is primarily based on analytical measurements derived from standard laboratory techniques:
- Spectrophotometric measurements: Absorbance at 260 nm (for RNA yield), A260/A280 ratio (for RNA purity).
- Quantitative Reverse Transcription-Polymerase Chain Reaction (Q-RT-PCR) assays: Using CFOS and IL1B transcripts normalized to 18S rRNA (for RNA integrity and relative transcription levels). This involves comparing threshold cycle (Ct) values.
- Electropherograms (BioAnalyzer): For RNA purity and integrity.
- Beta-actin PCR: To determine genomic DNA contamination.
- Biological assays: Proteinase K and DNase I activity tests.
- Physical and chemical property tests: pH, conductivity, density, draw volume, liquid additive volume, closure performance.
- Microbiological assays: Bioburden analysis.
8. Sample Size for the Training Set
The document does not explicitly describe a separate "training set" in the context of machine learning or AI algorithms, as this is not an AI-based device. Instead, the studies detail the performance validation of the system. The various studies use different cohorts of human donors for the collection of blood samples to assess different aspects of the device's performance (e.g., 5 donors for K2EDTA comparator, 48 donors for PAXgene in initial RT-PCR assay validation, 14 and 30 donors for system precision/reproducibility, 10 donors for purity/DNA contamination, 10 donors for each in situ stability condition).
9. How the Ground Truth for the Training Set Was Established
As mentioned above, there is no "training set" in the AI sense for this device. The establishment of "ground truth" for the various performance metrics (RNA yield, purity, integrity, etc.) is through well-established and standardized laboratory analytical methods as described in point 7. These methods themselves are considered the "gold standard" for measuring these specific biochemical and molecular parameters.
Ask a specific question about this device
Page 1 of 1